Advanced Pharmaceutical Composition and Formulation Development Overview Pharmaceutical Composition and Formulation Development CEFPODOXIME 200MG + CLAVULANIC ACID 125MG TABLETS are a Pharmaceutical Solid Oral Dosage Formulation of two actives- Cefpodoxime and Clavulanic Acid The combination product should be a carefully engineered tablet formulation where the active drug components are blended with appropriate pharmaceutical excipients so as to achieve uniform dosage, suitable physical form and acceptable physical and chemical stability throughout shelf life. For pharmaceutical companies, this is a specialized product formulation combining both actives as in a single tablet dosage formulation. The primary active component, Cefpodoxime, is part of the formulation while Clavulanic Acid is the secondary components.
As this product formulation contains actives with differing physico-chemical properties, formulation scientists typically consider in-process material attrition such as particle size, bulk and tapped density, flow properties and compatibility studies prior to the final formulation to production process. The selection of excipients for the formulation would normally include a wide range of suitable diluents, binders, disintegrants, lubricants, glidants and other excipients. The formulation ultimately aims to produce Cefpodoxime and Clavulanic Acid tablets with uniform physical and chemical properties, adequate mechanical strength and balanced pharmaceutical properties. Pharmaceutical Ingredients Integration The detailed formulation process development for CEFPODOXIME 200MG + CLAVULANIC ACID 125MG TABLETS would normally require a well-controlled integration of actives in a sole dry powder or granular form.
Ensuring proper identification and control of Actives or materials is an important step to avoiding mix-ups and cross-contamination when dispensingmaterials out for manufacturing purposes. Particle size, density and flow properties can also significantly influence the quality of the final blend. Consequently, Actives like Cefpodoxime and Clavulanic Acid may require specially controlled sieving, milling and premixing process stepswithin the manufacturing procedure.
Compatibility of Actives with the excipients used in the formulation is similarly an important consideration and laboratory formulation trials can evaluate potential changes in apparent clarity, moisture absorbance, assay and other pharmaceutical attributes during storage. Based on the granulation process design or direct compression formulation design, appropriate granulation may be necessary to increase flow properties and harden the formulation, or direct compression may be used when active materials exhibit appropriate physical properties. Ingredient selection is similarly important, with different excipients and their various physical properties influencing the manufacturing process and final finished product physical properties.
Process parameters need to be selected and controlled to ensure good product performance from the start of the process to completion. Tablets Manufacturing and Compression Technology Themanufacturing process for CEFPODOXIME 200MG + CLAVULANIC ACID 125MG TABLETS is generally a multi-stage controlled process. Raw materials are received, identified, sampled and releasedfor manufacturing following established quality procedure, and then in-processmaterials are dispensed accurately according to the master manufacturing formula, with potential Sieving and controlled blending of powders prior to formulation processing. Extra processing involving wet or dry granulation as part of this process is performed to produce granules of the correct size and physical characteristics, after which the granulate material is lubricated before compression or compression/formulation processing, with parameters monitored at each stage to ensure target tablet weight, hardness, thickness, appearance, etc., are maintained – excessive compression levels can influence disintegration and other properties, while insufficient compression levels produce weak, fragile tablets.
Quality Control Parameters of Finished Tablets The requirements for finished-product testing of CEFPODOXIME 200MG + CLAVULANIC ACID 125MG TABLETSis a widely established practice. The Finished-product test parameters are in accordance with the product specification and other regulatory requirements, and may include identification, assay of the individual Actives, related substance testing, dissolution, disintegration, weight variation or average weight, and other parameters of interest. Identification of the components in a combined formulation is especially important, with methods capable of differentiating Actives being used by analytical quality-control laboratories in CF testing.EMA, WHO and other pharmacovigilance agencies may specify the use of a limited number of assays with acceptable lower limits for assay of the different actives to ensure compliant products on market.
PharmaQC has also found that physical assessments of the blend or final tablets provide significant indicators of quality consistency between batches, with visual inspection for surface integrity and the absence of cracks, chips, surface irregularities, coloration or other defectstaken into account as is weight variation for each tablet. Dissolution tests are performed as an indication of the release behavior of Actives from the matrix, while stability related testing may include all others including assay, degradation peaks, moisture content and so on.STORAGE AND PACKAGINGThe choice of a packaging system for CEFPODOXIME 200MG + CLAVULANIC ACID 125MG TABLETSis as critical as the formulation development, with suitable material selection required to ensure protection from environmental factors. Any requisite stability packaging can be implemented for long storage periods and other storage requirements under appropriate manufacturing conditions and shelf -life indications.
Labels with batch identification, expiry dates and other relevant information are created for stability guidance and other regulatory demands – this can be printed directly onto the packaging or as separate information. Application in Product Portfolio and PCD Pharma Franchise The pcd pharma products portfolio are generally comprised of well controlled pharmaceutical formulations with detailed attention to quality, stability and comprehensive documentation. CEFPODOXIME 200MG + CLAVULANIC ACID 125MG TABLETS can offer specific formulation quality, consistency in manufacturing and packaging standards, and overall systematic quality checks without the inclusion of other active ingredients and other formulation components. For the pharmaceutical companies / distributors/ importers, this product can be a significant part of an organized portfolio of defined product ranges and well-established formulas.
This range can be made economically available for pcd pharma franchise business opportunities in India, catering to demand from pharmaceutical franchisees and other pharmaceutical companies.
Due to a robust product format, quality assurance and clear documentation can contribute to a well-organized portfolio of complementary products. As part of the product portfolio, this combination can be supplemented with other pharmaceutical active ingredients, formulations and dosages. A reliable franchise base with a strong quality system could generate additional product lines in the office, manufacturing facility or distribution organization.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech